Sinocelltech Group Limited

688520

CNE100003ZL3

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
49.75 ^CNY	+5.72%		+14.55%	-7.65%

Apr. 18	Sinocelltech Forecasts Return to Profit in Q1	MT
Apr. 18	China stocks track Asian markets higher	RE

Sinocelltech Group Limited Announces Earnings Results for the First Half of 2020

August 26, 2020

Sinocelltech Group Limited announced earnings results for the first half of 2020. For the first half, the company reported basic loss per share of CNY 0.88.

Latest news about Sinocelltech Group Limited

Sinocelltech Forecasts Return to Profit in Q1	Apr. 18	MT
China stocks track Asian markets higher	Apr. 18	RE
Sinocelltech's Unit Gets Nod to Trial Tumor Drug	Apr. 11	MT
Sinocelltech Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
Sinocelltech Gets Green Light to Trial SCTC21C Injection; Shares Up 3%	Jan. 19	MT
Sinocelltech Group Limited announced a financing transaction	Jan. 02	CI
Sinocelltech Group Limited Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Sinocelltech Group Limited(XSSC:688520) added to S&P Global BMI Index	23-09-18	CI
Sinocelltech Group Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-22	CI
Sinocelltech Unit Gets Nod for Cancer Drug Registration, COVID-19 Vaccine Trial	23-06-30	MT
Sinocelltech Gets Certification for Registration of Adalimumab Injection	23-06-13	MT
China Begins COVID-19 Vaccination Using Four-Valent Vaccine	23-05-30	MT
Sinocelltech Rents Building for 290 Million Yuan	23-05-26	MT
Sinocelltech CFO Retires; Successor Named	23-04-26	MT
Sinocelltech Group Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Sinocelltech’s Second COVID-19 Vaccine Wins Nod for Emergency Use in China	23-03-23	MT
Sinocelltech Group Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-23	CI
Sinocelltech’s COVID-19 Vaccine Wins Nod For Emergency Use in China; Shares Slump 11%	22-12-05	MT
Sinocelltech to Invest $34 Million in New Australian Unit; Shares Up 5%	22-11-15	MT
Sinocelltech Cleared to Launch Clinical Trial for COVID-19 Vaccine	22-11-10	MT
Sinocelltech Raises $67 Million From Share Placement	22-11-07	MT
Sinocelltech Group Limited Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Sinocelltech Group Limited Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-23	CI
Sinocelltech Group Limited Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-26	CI
Sinocelltech Group Limited Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-24	CI

Chart Sinocelltech Group Limited

Duration

Period

More charts

Sinocelltech Group Ltd is a China-based company mainly engaged in the research, development and industrialization of biopharmaceutical products. The Company focuses on monoclonal antibodies, recombinant proteins and vaccine products. Its main products are SCT800, SCT200, SCT-I10A, SCT400, SCT510, SCT1000 and SCT630, among others. The Company is also engaged in asset leasing business and payment collection business.

Sector

Biotechnology & Medical Research

Calendar

2024-08-20 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Sinocelltech Group Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

49.75 CNY

Average target price

69 CNY

Spread / Average Target

+38.69%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SINOCELLTECH GROUP LIMITED	-7.65%	3.06B
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+0.52%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-8.96%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs